<span id="midArticle_start"/>May 4 (Reuters) - Veloxis Pharmaceuticals A/S :
<span id="midArticle_0"/>* Envarsus XR demonstrates improved pharmacokinetic profilein African-American transplant recipients
<span id="midArticle_1"/>* Once-daily Envarsus XR (tacrolimus extended-releasetablets), an investigational new drug under FDA review for theprevention of organ rejection in adult kidney transplantpatients, demonstrated that a lower dose of once-daily EnvarsusXR in African-American kidney transplant patients is sufficientto achieve therapeutic tacrolimus blood concentrations, comparedto twice-daily immediate release tacrolimusSource text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_2"/>
<span id="midArticle_0"/>* Envarsus XR demonstrates improved pharmacokinetic profilein African-American transplant recipients
<span id="midArticle_1"/>* Once-daily Envarsus XR (tacrolimus extended-releasetablets), an investigational new drug under FDA review for theprevention of organ rejection in adult kidney transplantpatients, demonstrated that a lower dose of once-daily EnvarsusXR in African-American kidney transplant patients is sufficientto achieve therapeutic tacrolimus blood concentrations, comparedto twice-daily immediate release tacrolimusSource text for Eikon: Further company coverage: (Gdynia Newsroom)
<span id="midArticle_2"/>
via Smart Health Shop Forum http://ift.tt/1K66zGl
No comments:
Post a Comment